Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression - PubMed (original) (raw)

Tait D Shanafelt et al. J Clin Oncol. 2008.

No abstract available

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

Figures

Fig 1

Fig 1

Karyotype evolution and survival. (A) Overall survival from date of repeat fluorescent in situ hybridization (FISH) analysis based on whether or not patients had clonal evolution (n = 63). (B) Overall survival from date of clonal evolution based on the type of cytogenetic defect acquired (n = 17).

Fig 2

Fig 2

Stability and reproducibility of CD49d evaluated by flow cytometry. (A) Comparison of CD49d expression on chronic lymphocytic leukemia peripheral blood samples tested as either fresh samples or on thawing after storage at −80°C (n = 14). The intraclass correlation coefficient between the two assays was 0.983 (95% CI, 0.948 to 0.995). (B) Expression of CD49d over time on sequential samples from patients (n = 32) who had samples at multiple time points over a 3-month to 4-year interval. The intraclass correlation coefficient between the two assays was 0.952 (95% CI, 0.908 to 0.976). Dotted horizontal line represents the 45% threshold used to separate patients expressing and not expressing CD49d. One (3%) of 32 patients had a change in CD49d classification over time. (C) Comparison of a two-color (CD19, CD49d) verses three-color (CD19, CD5, CD49d) flow cytometry strategy for evaluating CD49d. (○) Fresh specimens (n = 35); (+) frozen specimens (n = 34). The solid line represents the x = y line (ie, for values on this line, two-color and three-color results are the same). Dotted lines indicate a 5% difference between x and y values. The two assays yielded nearly identical results in all cases, with an intraclass correlation coefficient of 0.999 (95% CI, 0.999 to 1.000) for comparisons on both fresh and frozen samples.

Similar articles

Cited by

References

    1. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634–4641. - PubMed
    1. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916. - PubMed
    1. Catovsky D, Richards S, Matutes E, et al. Fludarabine plus cyclophosphamide improves response and progression-free survival in chronic lymphocytic leukemia: A report from the LRF CLL4 Trial. Lancet. 2007;370:230–239. - PubMed
    1. Shanafelt T, Geyer SM, Bone ND, et al. CD49D Expression is an independent predictor of overall survival in patients with CLL: A prognostic parameter with therapeutic potential. Br J Haematol. 2008;140:537–546. - PMC - PubMed
    1. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111:865–873. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources